Immuneering logo

ImmuneeringNASDAQ: IMRX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 July 2021

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$62.10 M
-90%vs. 3y high
38%vs. sector
-vs. 3y high
-vs. sector
-73%vs. 3y high
41%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 23:59:35 GMT
$2.00+$0.06(+3.09%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

IMRX Latest News

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
zacks.com16 September 2024 Sentiment: POSITIVE

Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
globenewswire.com12 September 2024 Sentiment: POSITIVE

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
globenewswire.com31 July 2024 Sentiment: POSITIVE

- IMM-1-104 Fast Track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma (PDAC); provides potential to accelerate IMM-1-104's path to U.S. FDA submission for PDAC - - Phase 2a trial of IMM-1-104 includes multiple arms open to first-line pancreatic cancer patients, as well as arms open to patients with second-line pancreatic cancer, RAS-mutant melanoma, and RAS-mutant lung cancer - - Company expects initial data from multiple arms of its Phase 2a clinical trial in the second half of 2024 - CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its lead clinical-stage program, IMM-1-104, as a first-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC).

Immuneering to Present at the Jefferies Global Healthcare Conference
globenewswire.com29 May 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 5-6, 2024, to discuss the company's pipeline, platform, and business strategy.

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Seeking Alpha19 March 2024 Sentiment: POSITIVE

Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024.

Immuneering (IMRX) Plummets 71% in One Week: Here's Why
Zacks Investment Research18 March 2024 Sentiment: NEGATIVE

Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
GlobeNewsWire05 March 2024 Sentiment: NEGATIVE

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 5-10 in San Diego, California.

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewsWire04 October 2023 Sentiment: POSITIVE

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will present preclinical data on IMM-1-104, its lead clinical-stage program, and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston.

Immuneering Corp.: Early Stage Promise, But Long-Term Investment
Seeking Alpha07 July 2023 Sentiment: POSITIVE

IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going to take time.

Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet
Zacks Investment Research05 July 2023 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

What type of business is Immuneering?

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

What sector is Immuneering in?

Immuneering is in the Healthcare sector

What industry is Immuneering in?

Immuneering is in the Biotechnology industry

What country is Immuneering from?

Immuneering is headquartered in United States

When did Immuneering go public?

Immuneering initial public offering (IPO) was on 30 July 2021

What is Immuneering website?

https://immuneering.com

Is Immuneering in the S&P 500?

No, Immuneering is not included in the S&P 500 index

Is Immuneering in the NASDAQ 100?

No, Immuneering is not included in the NASDAQ 100 index

Is Immuneering in the Dow Jones?

No, Immuneering is not included in the Dow Jones index

When was Immuneering the previous earnings report?

No data

When does Immuneering earnings report?

The next expected earnings date for Immuneering is 28 February 2025